ArticleCirculation reports2026
Combination of Skin Adhesives and Vascular Closure Device for Complete Hemostasis After Catheter Ablation.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the use of vascular closure devices (VCDs) following catheter ablation for atrial fibrillation (AF) effectively shortening postprocedural immobilization time, they carry the risk of subcutaneous hemorrhage, which often requires extended bed rest, exceeding 2 h. We assessed whether combining skin adhesives (SAs) with a VCD can safely enable earlier mobilization without increasing bleeding risk. Methods and Results: This retrospective analysis evaluated 244 patients who underwent catheter ablation for AF between April 2022 and March 2024 and achieved successful hemostasis with a VCD. Patients with cardiac surgery history, dual antiplatelet therapy, cognitive impairment, or intensive care needs were excluded. Ultrasound-guided VCDs were used in all procedures. The SA group (n=162) received Dermabond Mini® with immediate post-anesthesia mobilization. The control group (n=82) underwent angio-roll compression and followed physician-guided rest protocols. Endpoints included rest duration, total procedural time, hemorrhagic events, opioid administration, and length of hospital stay. Despite immediate post-anesthesia mobilization, the SA group showed shorter time to ambulation (129±95 vs. 513±440 min, P<0.01) with lower rates of hemorrhagic complications (BARC type 1: 1.2% vs. 6.1%, P=0.044; BARC type 2: 5.6% vs. 23.2%, P<0.01) than the control group. Procedural duration was comparable. The SA group required less fentanyl. Conclusions: The combination of SA and VCDs enabled immediate post-anesthesia mobilization without increasing bleeding complications, improving patient outcomes and resource utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.